Showing results (61-70 of 91) with videos related to
Sort By:
Pageof 10
Cancer Medicine|January 25, 2023
Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphomaXiaoshuang Kong, Xudong Zhang, Mengjie Ding, et al.Journal of Cellular Biochemistry|March 3, 2019
c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphomaLinan Zhu, Xudong Zhang, Xiaorui Fu, et al.Gut|December 9, 2024
Butyrate-producing <i>Faecalibacterium prausnitzii</i> suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT pathwayZhuangzhuang Shi, Min Li, Chen Zhang, et al.Oncotarget|April 18, 2018
An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphomaLing Li, Sa Xiao, Lei Zhang, et al.Cancer Cell International|October 11, 2018
Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?Xudong Zhang, Xiaorui Fu, Meng Dong, et al.Leukemia & Lymphoma|January 19, 2023
Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphomaMeng Lin, Xiaolong Wu, Lei Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2016
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in ChinaXin Li, Yingying Cui, Zhenchang Sun, et al.Journal of Neuro-Oncology|August 16, 2018
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trialJingjing Wu, Lingling Duan, Lei Zhang, et al.Oncology Letters|February 13, 2016
Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphomaYingying Cui, Zhenchang Sun, Xin Li, et al.Hematological Oncology|June 1, 2021
Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous systemXingying Li, Hui Yu, Xiaorui Fu, et al.Pageof 10